AlphAIAlphAI — Financial news for AI agents
investing.comOCT 231 min read$PHVS

BofA upgrades Pharvaris stock rating on oral HAE treatment potential

BofA upgraded Pharvaris (PHVS) to Buy with a $44 price target, citing potential in its oral HAE treatment. The stock trades at $30.68, up 10.6% in a week. Positive phase 3 data and strong analyst ratings highlight its prospects, despite risks like market adoption and competition.

Original reporting
investing.com
Published Oct 23, 2026, 11:22 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 11:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$PHVS
Bullish
high confidence
Mentioned
$PHVS
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$PHVSBullishHigh
01

Why it matters

The Buy rating and $44 target provide a clear catalyst for short‑term buying pressure.

02

Market read

Analyst upgrade on a micro‑cap biotech with recent positive trial data, offering a near‑term trade idea.

03

What to watch

Potential competition from injectable therapies and regulatory timelines beyond 2027.

Relevance 7/10Novelty 6/10Timing: today

Background

Pharvaris reported positive Phase 3 oral HAE data in September 2024; the upgrade reflects fresh analyst confidence.

Company-level read

Ticker impact

$PHVSBullishHigh confidence
Context

BofA upgraded Pharvaris to Buy with a $44 target, citing strong Phase 3 data and a 10.6% recent price gain.

Expected impact

likely upward pressure as traders price in the new Buy rating and target.

Evidence & confidence

Upgrade is a fresh, actionable recommendation with a concrete price target, providing a clear catalyst for buying.

Market effects

Sector

Positive for the rare‑disease biotech sector as the upgrade highlights clinical progress.

Regional

US biotech market may see modest buying interest.

Global

Limited to investors tracking rare‑disease therapeutics.

Counterpoint

What could challenge this read

The upgrade may be premature if long‑term safety or market adoption issues emerge.

Key entities

  • analyst
    BofA Securities

    Upgraded Pharvaris to Buy and set a $44 price target.

  • company
    Pharvaris B.V.

    Biotech developing oral HAE treatment deucrictibant.

Read at source← All news

StoryBank of America upgrades Pharvaris to Buy with $44 price target

Also covered by

1 outlet

Related articles

OCT 8
$PHVSMedAI 8/10

Pharvaris HAE drug shows faster symptom relief in Lancet study

Pharvaris' phase 3 study of deucrictibant IR for HAE attacks, published in The Lancet, met all endpoints, showing faster symptom relief and resolution than placebo. The drug was well-tolerated. FDA and EMA reviews are ongoing with decisions expected in 2027. According to the company, the study results support the drug's efficacy and safety.

investing.com5 min
OCT 8
$PHVSMedAI 8/10

Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet

Pharvaris (PHVS) announced positive results from the RAPIDe-3 study of deucrictibant IR for treating HAE attacks, published in The Lancet. The treatment showed rapid symptom relief and resolution, with a well-tolerated safety profile. The company's NDA and MAA for deucrictibant IR are under regulatory review, with a PDUFA target date of April 23, 2027.

globenewswire.com5 min
OCT 6
$PHVSMedAI 8/10

Pharvaris stock reiterated Buy at H.C. Wainwright on HAE therapy potential

H.C. Wainwright reiterated a Buy rating and $60 price target on Pharvaris (PHVS) due to positive Phase 3 data for deucrictibant, showing an 83% reduction in HAE attacks. The firm sees potential in treating acquired angioedema and expects FDA approval by April 2027. PHVS shares are down 19% since September 2026, trading at $30.49 with a $2.14B market cap. Analysts project significant upside, with price targets ranging from $41 to $79.

investing.com2 min